Related Experiment Video
Updated: May 13, 2026
06:23
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Screening for dementia and investigating its causes.
1University of California, Los Angeles.
Annals of Internal Medicine
|July 15, 1991
Summary
Primary care physicians can effectively screen for cognitive impairment using specific mental status tests. However, routine ancillary tests are often unwarranted for diagnosing dementia causes.
Area of Science:
- Neurology
- Primary Care Medicine
- Diagnostic Testing
Background:
- Dementia diagnosis relies on clinical assessment and cognitive screening.
- Primary care physicians require guidance on effective diagnostic tools.
Purpose of the Study:
- To evaluate the diagnostic value of mental status findings and ancillary tests for dementia in primary care.
- To inform clinicians about the utility and limitations of dementia screening methods.
Main Methods:
- Systematic review of studies identified via MEDLINE and bibliographies.
- Data extraction focused on sensitivity, specificity, and likelihood ratios.
- Re-analysis of data to assess alternative cut-off values and clinical utility.
Main Results:
- Normal results on tests like serial 7s, digit span, recall, and clock drawing significantly decrease dementia probability.
- Abnormal results moderately increase dementia odds; Mini-Mental State Examination scores show varying diagnostic utility.
- The effectiveness of tests for identifying dementia causes depends on pre-test probability.
Conclusions:
- Clinicians should be familiar with the strengths and weaknesses of cognitive screening tools.
- Routine use of VDRL, cerebral imaging, cobalamin, or folate levels is not recommended for investigating dementia causes.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...